所有图片(1)
About This Item
线性分子式:
H2NC(=NH)NHC6H4CO2H · HCl
CAS号:
分子量:
215.64
Beilstein:
3718032
EC號碼:
MDL號碼:
分類程式碼代碼:
12352100
PubChem物質ID:
NACRES:
NA.22
推荐产品
化驗
99%
形狀
solid
mp
285 °C (dec.) (lit.)
儲存溫度
2-8°C
SMILES 字串
Cl[H].NC(=N)Nc1ccc(cc1)C(O)=O
InChI
1S/C8H9N3O2.ClH/c9-8(10)11-6-3-1-5(2-4-6)7(12)13;/h1-4H,(H,12,13)(H4,9,10,11);1H
InChI 密鑰
YETFLAUJROGBMC-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
4-Guanidinobenzoic acid hydrochloride is a guanidine derivative. Quality standard of 4-guanidinobenzoic acid hydrochloride has been investigated.
應用
4-Guanidinobenzoic acid hydrochloride may be used in ELISA inhibition assay of mouse antiserum. It may be used in the synthesis of human acrosin inhibitor 4′-acetaminophenyl 4-guanidinobenzoate hydrochloride.2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
S Ookawara et al.
European journal of clinical pharmacology, 51(2), 149-151 (1996-01-01)
Nafamostat mesilate, a potent protease inhibitor, is widely used for the treatment of pancreatitis, disseminated intravascular coagulation and as an anticoagulant in haemodialysis. However, hyperkalaemia associated with nafamostat mesilate has been reported. It is thought to be due to decreased
M K Ramjee et al.
Thrombosis research, 98(6), 559-569 (2000-07-19)
Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, is active against a number of the serine proteases involved in coagulation. This has been proposed as the basis of its anticoagulant activity. We investigated the reaction of Nafamostat with bovine pancreatic
I Midgley et al.
Xenobiotica; the fate of foreign compounds in biological systems, 24(1), 79-92 (1994-01-01)
1. The metabolic fate of N,N-dimethylcarbamoylmethyl 4-(4-guanidino[14C]benzoyloxy)phenylacetate methanesulphonate (14C-camostat mesylate) was investigated after i.v. administration to man (12-h infusion), and to rat and dog (bolus injection). 2. Renal excretion (mainly in 24 h) accounted for at least 80% dose in
Di-ya L, et al.
Chinese Pharmaceutical Journal, 3, 28-28 (2010)
S Muto et al.
British journal of pharmacology, 111(1), 173-178 (1994-01-01)
1. The present experiments were undertaken to determine the mechanism(s) of hyperkalaemia caused by nafamostat mesilate (NM), a serine-protease inhibitor. 2. We investigated the effects of luminal addition of two metabolites of NM, p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN), on
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门